Effects of psychotropic drugs on weight

Psychiatric Annals

Volumn 29, Issue 10, 1999, Pages 580-594

  Sussman, Norman ^a,b   Ginsberg, David ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033448412     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19991001-08     Document Type: Article

References (106)

1. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998; 105:145-150.
2. Huether G, Zhou D, Schmidt S, Wiltfang J, Ruther. Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry. 1997;41:1174-1180.
3. Jahng JW, Houpt TA, Kim SJ, Jon TH, Son JH. Neuropeptide Y mRNA and serotonin innervation in the arcuate nucleus of anorexia mutant mice. Brain Res. 1998;790:67-73.
4. Dryden S, Frankish HM, Wang Q, Pickarence L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience. 1996;72:557-566.
5. Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull. 1988;24:220-223.
6. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993;87:141-145.
7. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol. 1993;13(suppl 2): 18S-22S.
8. Darga LL, Carol-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr. 1991;54:321-325.
9. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170-1176.
10. Mackle M, Kocsis J. Effects on body weight of the SSRI citalopram. Presented at the annual meeting of the American College of Neuropharmacology; December 1998.
11. Fogelson DL. Weight gain during fluoxetine treatment. J Clin Psychopharmacol. 1991;11:220-221.
12. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol. 1996;11:273-278.
13. Agren H, Aberg-Wistedt A, Akerblad A-C. NR366 sertraline versus paroxetine in major depression: a multicentre double-blind, 24-week comparison. Presented at the annual meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
14. Fava M, Rosenbaum JF. Treatment-emergent side effects of the newer antidepressants. In: Jefferson JW, Greist JH, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 1996. Philadelphia: W. B. Saunders; 1996:13-29.
15. Joubert AF, Gagiano CA, Joubert G. Antidepressants and weight: comparative study of four antidepressants and their effect on weight. Eur Neuropsychopharmacol. 1996;6(suppl 3):143.
16. Amsterdam JD, Garcia-Espana F, Goodman D, Hooper MB, Hornig-Rohan M. Breast enlargement during chronic antidepressant therapy. J Affect Disord. 1997;46:151-156.
17. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry. 1995;56:288-296.
18. Feighner JP, Gardner EA, Johnston JA, Batey SR. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991;52:329-335.
19. Goodnick PJ, Kremer C, Wingard P. Weight change during mirtazapine therapy. Primary Psychiatry. 1998:103-108.
20. Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. CNS Drugs. 1998;9:135-151.
21. Martinez JA, Velasco JJ, Urbistondo MD. Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients. J Am Coll Nutr. 1994;13:192-197.
22. Allison DB, Mentore JL, Heo M, et al. Weight gain associated with conventional and newer antipsychotics: a metaanalysis. Presented at the 21st Annual Collegium Internationale Neuro-Psychopharmacologicum Congress; Glasgow, Scotland; July 13-16, 1998.
23. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull. 1995;21:463-472.
24. Doss FW. The effect of antipsychotic drugs on body-weight: a retrospective review. J Clin Psychiatry. 1979;40:528-530.
25. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 1992;149:689-690.
26. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149:68-72.
27. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry. 1994;55(9 suppl B):157-160.
28. Bustillo JR, Buchanan RW, Irish D, et al. Differential effects of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153:817-819.
29. Ghaeli P, Dufresne RL. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy. 1995;15:382. Abstract.
30. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53:2079-2081.
31. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 1998;21:245-250.
32. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156:1270-1272.
33. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57(suppl 11):53-60.
34. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58(suppl 10):13-17.
35. Osser DN, Najarian D, Berman I, et al. Olanzapine increases weight and triglyceride levels. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
36. Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999;156:1471-1472. Letter.
37. Amery W, Zuiderwijk P, Brecher M, et al. Safety profile of risperidone. Presented at the Thirty-Sixth Annual Meeting of the American College of Neuropsychopharmacology; Kamuela, Hawaii; December 8-12, 1997.
38. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest. 1999;19:99-104.
39. Chou JCY, Serper MR. Ziprasidone: a new highly atypical antipsychotic. For Essential Psychopharmacology. 1998; 2:463-485.
40. Ganguli R, Brar JS, Ayrton Z. Weight gain with atypical antipsychotic medications. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
41. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999;156:312-314.
42. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-363.
43. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry. 1994;151:1395. Letter.
44. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry. 1994;151:1520-1521. Letter.
45. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 1997;58:108-111.
46. Hagg S, Joelsson J, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-299.
47. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778-783.
48. Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998;59:687-698. Letter.
49. Lindenmayer JP, Patel R. Olanzapine-induces ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999;156:1471. Letter.
50. Sobel M, Jaggers ED, Frantz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry. 1999;60:556-557. Letter.
51. Zoler ML. Antipsychotics linked to weight gain, diabetes. Clinical Psychiatry News. 1999;27:20.
52. Keskiner A, El Toumi A, Bousquet T. Psychotropic drugs, diabetes, and chronic mental patients. Psychosomatics. 1973;14:176-181.
53. Schwartz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry. 1968;125:253-255.
54. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci. 1991;49:101-109.
55. Uvnas-Moberg K, Ahlenius S, Alster P, et al. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagon in the rat. Neuroendocrinology. 1996;63:269-274. Abstract.
56. Chaouloff F, Laude D, Baudrie V. Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol. 1990;187:435-443.
57. Yamada J, Sugimoto Y, Yoshikawa T, et al. The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycemia in rats. Life Sci. 1995;57:819-825. Abstract.
58. Kerry FJ, Liebling LI, Owen G. Weight changes in lithium responders. Acta Psychiatr Scand. 1970;46:238-243.
59. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol. 1990;5:217-225.
60. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort: 3. Tremor, weight gain, psychological complaints. Acta Psychiatr Scand. 1988;78:434-441.
61. Vendsborg PB, Bech P, Rafaelson OJ. Lithium treatment and weight gain. Acta Psychiatr Scand. 1976;53:139-147.
62. Mellerup ET, Plenge PK, Rafaelson OJ. Lithium and insulin effects on carbohydrate and electrolyte metabolism. Dan Med Bull. 1974;21:88-91.
63. Battacharya G. Influence of lithium on glucose metabolism in rats and rabbits. Biochem Biophys Acta. 1964;93:644-646.
64. Clausen T. The relationship between the transport of glucose and cations across cell membranes in isolated tissues: IV. The "insulin-like" effect of lithium. Biochem Biophys Acta. 1968;150:66-72.
65. Birnbaum L, Pohl SL, Rodbell M. Adenyl cyclase in fat cells. J Biol Chem. 1969;244:3468-3476.
66. Krulic R, Janko L, Cerny M. Metabolism of lipids in lithium-administered rats. Acta Univ Carol [Med] (Praha). 1971;17:533-540.
67. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ. 1981;283:577-581.
68. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;69:65-69.
69. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open label study. Headache. 1991;21:71-74.
70. Sharpe C, Buchanan N. Juvenile myoclonic epilepsy: diagnosis, management, and outcome. Med J Aust. 1995;162:133-134.
71. Dulac O, Steru D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev. 1986;8:47-52.
72. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332-372.
73. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients: relation to obesity. Epilepsy Res. 1993;16:55-64.
74. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism. 1992;41:666-670.
75. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1383-1388.
76. Sussman N, Ginsberg D. Valproate and risk of polycystic ovary syndrome. Primary Psychiatry. 1998;5:42-48.
77. Joffe RT, Post RM, Uhde TW. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry. 1986;47:313-314.
78. Lampl Y, Eshel Y, Rapaport A, et al. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol. 1991;14:251-255.
79. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med. 1992;327:765-771.
80. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry. 1994;57:682-687.
81. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol. 1995;37:97-108.
82. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry. 1995;152:1399. Letter.
83. Mellick GA, Mellicy LB, Mellick JD. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage. 1995;10:265-266.
84. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998;43:305. Letter.
85. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155:992-993. Letter.
86. Markowitz JS, Finkenbine R, Myrick H, et al. Gabapentin abuse in a cocaine user: implications for treatment? J Clin Psychopharmacol. 1997;17:423-424.
87. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1632. Letter.
88. Gidal BE, Maly MM, Nemire RE, et al. Weight gain and gabapentin therapy. Ann Pharmacother. 1995;29:1048. Letter.
89. DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997;19:394-396.
90. Baulac M, Cavalcanti F, Semah F, et al. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. Seizure. 1998;7:55-62.
91. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry. 1996;153:1236.
92. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res. 1997;72:145-148.
93. Yatham LN, Kusumakar V, Parikh SV, et al. Bipolar depression: treatment options. Can J Psychiatry. 1997;42 (suppl 2):87S-91S.
94. Leach MJ, Baxter MG, Critchley MAE. Neurochemical and behavioural aspects of lamotrigine. Epilepsia. 1991;32:S4-S8.
95. Southam E, Kirkby D, Higgins GA, et al. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998;358:19-24.
96. Betts T, Goodwin G, Withers RM, et al. Human safety of lamotrigine. Epilepsia. 1991;32(suppl 2):S17-S21.
97. Isojarvi JIT, Rattya J, Myllyla W, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43:446-451.
98. Montouris G, Mirza WU, Biton V, et al. Effects of lamictal and depakote monotherapy on body weight in patients with epilepsy: interim analysis of a randomized, double-blind clinical trial. Presented at the 51st Annual Meeting of the American Academy of Neurology; Toronto, Ontario, Canada; April 17-24, 1999.
99. Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm. 1998;55:554-562.
100. Marcotte DB. Use of the new antiepileptic drug topiramate as a mood stabilizer. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
101. Calabrese JR, Shelton MD, Keck PE, et al. Emerging trends in the management of psychiatric illness. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
102. Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy. Epilepsia. 1997;38(suppl 3):58.
103. Norton J, Potter D, Edwards K. Sustained weight loss with topiramate. Epilepsia. 1997;38(suppl 3):60.
104. Lichter PR. Reducing side effects of carbonic anhydrase inhibitors. Ophthalmology. 1981;88:266-269.
105. Meyer JS, Gotoh F, Tazoki Y. Inhibitory action of carbon dioxide and acetazolamide in seizure activity electroencephalography. Clin Neurophysiol. 1961;13:762-775.
106. United States Pharmacoepia Drug Information (USP-DI). Carbonic Anhydrase Inhibitors (Systemic). Taunton, MA: Micromedex; 1998:729.